My Portfolio
My Watchlists
Profile & Performance
Smart Portfolio
Find & Follow Experts
Top Lists
Top Experts
Make Better, Data Driven Investment Decisions
TipRanks tools are all you need to make data-driven investment decisions, conduct comprehensive stock research, find new investment ideas, analyze your portfolio, and follow the best-performing Wall Street experts.
About Us
Plans & Pricing
Zomedica Pharmaceuticals (ZOM)
NYSE MKT:ZOM
ZOM nyse mkt
United States
Zomedica Pharmaceuticals

Zomedica Pharmaceuticals Stock Analysis & Ratings

Zomedica Pharmaceuticals Stock Analysis Overview

Smart Score
5
Neutral
1
2
3
4
5
6
7
8
9
10
Learn more about TipRanks Smart Score
The Zomedica Pharmaceuticals stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.

Stock Chart

ZOM

ZOM Stock Stats

Previous Close$0.44
Open$0.42
Bid0 x 0
Ask0 x 0
Today’s Range$0.42 - $0.429
52-Week Range$0.11 - $2.91
Volume8.26M
Average Volume24.42M
Market Cap$413.52M
Beta0.40
P/E Ratio-6.6
EPS-0.07
Earnings DateMar 02, 2022

Company Description

Zomedica Pharmaceuticals

Zomedica Pharmaceuticals Corp. operates as a development stage veterinary diagnostic and pharmaceutical company. It creates products for companion animals by focusing on the unmet needs of clinical veterinarians. The company was founded by Gerald L. Solensky, Jr. on January 7, 2013 and is headquartered in Ann Arbor, MI.
Sector
General
Industry
Drug Manufacturers
CEO
Robert Cohen / Robert Cohen
Employees
19
ISIN
CA98980M1095
Address
100 Phoenix Drive, Ann Arbor, MI, 48108, US

Financials


P/E Ratio Range

The price to earnings ratio. This is used by investors to assess a stock’s market price relative to its earnings.

ZOM FAQ

What was Zomedica Pharmaceuticals’s price range in the past 12 months?
Zomedica Pharmaceuticals lowest stock price was $0.11 and its highest was $2.91 in the past 12 months.
    What is Zomedica Pharmaceuticals’s market cap?
    Zomedica Pharmaceuticals’s market cap is $413.52M.
      What is Zomedica Pharmaceuticals’s price target?
      Currently, no data Available
      What do analysts say about Zomedica Pharmaceuticals?
      Not enough analysts have published a price target to provide an average price target.
      When is Zomedica Pharmaceuticals’s upcoming earnings report date?
      Zomedica Pharmaceuticals’s upcoming earnings report date is Mar 02, 2022 which is in 94 days.
        How were Zomedica Pharmaceuticals’s earnings last quarter?
        Zomedica Pharmaceuticals released its earnings results on Nov 12, 2021. The company reported -$0.01 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.01.
          Is Zomedica Pharmaceuticals overvalued?
          According to Wall Street analysts Zomedica Pharmaceuticals’s price is currently Overvalued.
            Does Zomedica Pharmaceuticals pay dividends?
            Zomedica Pharmaceuticals does not currently pay dividends.
            What is Zomedica Pharmaceuticals’s EPS estimate?
            Zomedica Pharmaceuticals’s EPS estimate for its next earnings report is not yet available.
            How many shares outstanding does Zomedica Pharmaceuticals have?
            Zomedica Pharmaceuticals has 108,040,000 shares outstanding.
              What happened to Zomedica Pharmaceuticals’s price movement after its last earnings report?
              Zomedica Pharmaceuticals reported an EPS of -$0.01 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -1.961%.
                Which hedge fund is a major shareholder of Zomedica Pharmaceuticals?
                Among the largest hedge funds holding Zomedica Pharmaceuticals’s share is Gotham Asset Management LLC. It holds Zomedica Pharmaceuticals’s shares valued at N/A.

                  What's Included in PREMIUM?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis